Fibrolamellar carcinoma is a rare liver cancer with limited systemic treatment options. This study identifies CXCR4 chemokine signaling as a key driver of immune exclusion in fibrolamellar carcinoma. Therapeutically targeting CXCR4 potentiates PD-1 blockade, together representing a new combination immunotherapy approach.
Fibrolamellar carcinoma is a rare liver cancer with limited systemic treatment options. This study identifies CXCR4 chemokine signaling as a key driver of immune exclusion in fibrolamellar carcinoma. Therapeutically targeting CXCR4 potentiates PD-1 blockade, together representing a new combination immunotherapy approach.